Macro

Search catalysts, news stories, and pressures, or browse the trust-weighted news feed below.

Home tech energy finance healthcare defense industrial consumer communication utilities real estate raw materials

← back

healthcare · sector mood

2012

year mood +0.24 · +0.14 to +0.30 across 12 mo

Monthly mood

bearish −1 +1 bullish

month values ▾

Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
+0.20	+0.20	+0.20	+0.20	+0.20	+0.14	+0.19	+0.30	+0.30	+0.30	+0.30	+0.30

The Supreme Court upheld the ACA in June, removing uncertainty and confirming the coverage expansion, while a multi-year biotech bull market began on strong FDA approvals; my mood rose steadily.

How this mood is scored ▾

Each day the model reads that day's news for the sector and asks, as someone who owns assets or makes their living in it: how am I feeling this month, and why? The month's mood is that running answer, tied to the specific events driving it (the story shown above). It leans on trusted, higher-impact reporting, and on the prior month when a month is quiet, so one loud headline can't swing it. The read updates daily through the month; once a month ends, its mood is locked. This year is read live from the news the pipeline actually collected (hover a bar for its story count). · last computed Jul 11, 2026

Top healthcare stories of 2012

Jun

Supreme Court upholds Obamacare individual mandate as constitutional tax cnn.com →

The U.S. Supreme Court upheld the Affordable Care Act's individual mandate by ruling it falls within Congress's taxing power, preserving President Obama's signature healthcare legislation. The 5-4 decision affirms key provisions like coverage for pre-existing conditions and dependent coverage to age 26, with major implications for insurers, Medicaid expansion, and the 2012 presidential election. Market uncertainty persists as Republicans vow repeal, while Democrats and healthcare stakeholders anticipate continued implementation of the law.

Jul

FDA approves Truvada for HIV prevention npr.org →

The FDA has approved Gilead Sciences' Truvada as the first drug to prevent HIV infection in high-risk individuals, requiring concurrent safe-sex practices. The approval, based on risk-benefit analysis by expert panels, expands preventive options amid persistent U.S. infection rates, primarily among gay and bisexual men. Market implications include increased demand potential despite high annual costs of $11,000–$14,000, balanced against safety monitoring and adherence requirements.